WO2020001643A1 - 甘露糖醛二酸的组合物在治疗血管性痴呆症中的应用 - Google Patents

甘露糖醛二酸的组合物在治疗血管性痴呆症中的应用 Download PDF

Info

Publication number
WO2020001643A1
WO2020001643A1 PCT/CN2019/093813 CN2019093813W WO2020001643A1 WO 2020001643 A1 WO2020001643 A1 WO 2020001643A1 CN 2019093813 W CN2019093813 W CN 2019093813W WO 2020001643 A1 WO2020001643 A1 WO 2020001643A1
Authority
WO
WIPO (PCT)
Prior art keywords
mannuronic acid
composition
total weight
use according
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2019/093813
Other languages
English (en)
French (fr)
Chinese (zh)
Inventor
耿美玉
辛现良
杜晓光
张真庆
丁健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shanghai Institute of Materia Medica of CAS
Shanghai Green Valley Pharmaceutical Co Ltd
Original Assignee
Shanghai Institute of Materia Medica of CAS
Shanghai Green Valley Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shanghai Institute of Materia Medica of CAS, Shanghai Green Valley Pharmaceutical Co Ltd filed Critical Shanghai Institute of Materia Medica of CAS
Priority to KR1020217001545A priority Critical patent/KR20210040039A/ko
Priority to US17/256,738 priority patent/US11406651B2/en
Priority to JP2020572804A priority patent/JP2021528458A/ja
Priority to EP19826046.5A priority patent/EP3815694A4/en
Priority to AU2019296854A priority patent/AU2019296854A1/en
Publication of WO2020001643A1 publication Critical patent/WO2020001643A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Definitions

  • the present invention relates to the application of the optimal composition of mannuronic acid obtained by biological activity screening method in the treatment of vascular dementia.
  • Vascular dementia refers to severe cognitive dysfunction syndrome caused by cerebrovascular disease.
  • the prevalence of VD in China is 1.1% to 3.0%, and the annual incidence is 5 to 9/1000 people. Its clinical practice is mainly to treat primary cerebrovascular disease and prevent VD.
  • vitamin E, vitamin C, and ginkgo biloba preparations are mainly used as adjuvant therapy, and there are no good treatments.
  • Mannuronic acid has been widely valued for its potential medicinal value.
  • Mannuronic acid is usually prepared from alginic acid through multiple steps.
  • the method for preparing oligomannuronic acid is as follows: the M-stage intermediate obtained above is heated under acidic conditions and further acidolyzed to obtain small fragments of mannuronic acid polymers in a desired molecular weight range.
  • the reducing terminal can be oxidized to a ring-opened sugar diacid.
  • Patent Documents 1 and 2 are hereinafter collectively referred to as prior patents, which are all incorporated herein by reference.
  • reaction process of the mannuronic acid disclosed in the prior patent can be represented by the following reaction equation (II), that is, the oxidizing group at the C1-position of the mannuronic acid at the reducing end of the oligomannuronic polysaccharide is oxidized to a carboxyl group.
  • a common oxidant is a basic copper sulfate solution, that is, a film reagent.
  • This oxidation method has been adopted in a prior patent. Specifically, under basic conditions, the reaction substrate is polymannuronic acid, namely The above M-stage intermediate is added to the copper sulfate solution and reacted in a boiling water bath for 15 minutes to 2 hours.
  • This method uses Cu2 + ions as an oxidant to oxidize aldehyde groups, and a brick red cuprous oxide precipitate is generated in the reaction. This reaction is often used to identify reducing sugars.
  • mannan oligosaccharide diacid has anti-Alzheimer's disease (AD) and anti-diabetic effects.
  • the pathogenesis of Alzheimer's disease and type 2 diabetes is closely related to amyloid ( ⁇ -amyloid and amylin).
  • ⁇ -amyloid and amylin amyloid
  • protein oligomers are produced, which further aggregate to form fibers.
  • These protein aggregates are cytotoxic, induce oxidative damage to mitochondria in the cells, and trigger a cascade of vascular dementia responses, causing a large number of neurons and ⁇ -cell damage, eventually leading to Alzheimer's disease and type II diabetes.
  • Mannan oligosaccharic acid targets amyloid and antagonizes the cascade response induced by it, thereby preventing and treating Alzheimer's disease and type 2 diabetes.
  • the prior patent CN106344593A discloses the application of alginate oligosaccharides and its derivatives in the treatment of vascular dementia, and discloses the pharmacological activity of tetrasaccharide-decagose mixture in the treatment of vascular dementia.
  • the invention relates to the use of a mannuronic acid oligosaccharide composition in the treatment of vascular dementia.
  • the invention also relates to a method for treating vascular dementia, which comprises administering to a patient in need of treatment a therapeutically effective amount of the mannuronic acid oligosaccharide composition according to the invention.
  • the mannuronic acid oligosaccharide composition used in the present invention has a specific composition and comprises a mannuronic acid having the formula (III) or a pharmaceutically acceptable salt thereof:
  • the total weight of n 1-5 of the mannuronic acid accounts for more than 60% of the total weight of the composition
  • Figure 1 is the mass spectrum of disaccharide, trisaccharide and tetrasaccharide in product A.
  • FIG. 2 is a mass spectrum of pentasaccharide, hexasaccharide, and heptose in product A.
  • FIG. 2 is a mass spectrum of pentasaccharide, hexasaccharide, and heptose in product A.
  • Figure 3 is a mass spectrum of octaose, nonasaccharide, and decasaccharide in product A.
  • FIG. 5 shows the effect of oligosaccharide composition, hexasaccharide, and comparative experimental samples on the number of errors in the dark avoidance experiment of vascular dementia mice induced by bilateral common carotid artery ligation; the abscissa reference numerals are the same as those in FIG. 4.
  • FIG. 6 shows the effect of oligosaccharide composition, hexasaccharide and comparative experimental samples on the escape latency of the water maze experiment of vascular dementia mice induced by bilateral common carotid artery ligation; the abscissa reference numerals are the same as FIG. 4.
  • FIG. 7 shows the effect of oligosaccharide composition, hexasaccharide, and comparative experimental samples on the number of times the vascular dementia mice cross the platform caused by bilateral common carotid artery ligation.
  • FIG. 8 shows the effects of oligosaccharide composition, hexasaccharide, and comparative experimental samples on the escape latency of the water maze experiment in vascular dementia rats caused by ligation of middle cerebral artery; the abscissas are the same as those in FIG. 4.
  • the invention relates to the use of a mannuronic acid oligosaccharide composition in the treatment of vascular dementia.
  • the invention also relates to a method for treating vascular dementia, which comprises administering to a patient in need of treatment a therapeutically effective amount of the mannuronic acid oligosaccharide composition according to the invention.
  • the mannuronic acid oligosaccharide composition according to the present invention comprises a mannuronic acid having the formula (III) or a pharmaceutically acceptable salt thereof:
  • the mannuronic acid oligosaccharide combination according to the present invention is a mixture of mannuronic acid with different polymerization degrees, and its main component is a mannuronic acid oligosaccharide with a polymerization degree of 2 to 10. It is known that among mannuronic acids, the most active sugars are 4-10 sugars, especially 6 sugars. However, the inventors have now discovered that adding a certain proportion of the less active 2-3 sugars to the 4-10 sugars with the highest activity, the biological activity does not decrease or even increase at the same quality of the administered dose.
  • the weight percentage content of each degree of polymerization of the mannuronic acid oligosaccharide in the mannuronic acid oligosaccharide composition of the present invention in the combination is: 5-25% of disaccharide, trisaccharide 15-30%, tetrasaccharide 15-28%, pentasaccharide 5-25%, hexasaccharide 2-20%, heptose 2-20%, octose 2-20%, nonaperose 2-20%, decasu 2 -20%.
  • the weight percentage content of oligosaccharides in the composition is: 5-25% disaccharides, 15-30% trisaccharides, 15-28% tetrasaccharides, 10-20% pentasaccharides, 5-15% hexasaccharides, Heptasaccharide is 3-10%, octose is 2-5%, nonaose is 1-5%, and decaose is 1-5%. More preferably, the weight percentage of oligosaccharides in the composition is: 10-20% disaccharides, 18-30% trisaccharides, 15-28% tetrasaccharides, 15-20% pentasaccharides, and 5-10% hexasaccharides. , Heptasaccharide 3-5%, octaose 2-5%, nonaose 1-3%, and ten sugar 1-3%.
  • the pharmaceutically acceptable salt is a sodium salt or a potassium salt.
  • the inventor of the present patent application found that when the above 9 oligosaccharides with new structure are compounded in a certain ratio, a highly active oligosaccharide composition can be obtained, the activity of which is higher than that of the most active hexasaccharide; especially It is a composition added with a certain proportion of disaccharides and trisaccharides, and its activity is higher than the composition without disaccharides and trisaccharides.
  • the ratio of each oligosaccharide in the high-activity oligosaccharide composition needs to be combined according to the following proportional relationship:
  • the medicament for treating vascular dementia according to the present invention comprises a mannuronic acid oligosaccharide composition comprising a mannuronic acid having the formula (III) or a pharmaceutically acceptable salt thereof, and one or more A pharmaceutically acceptable carrier.
  • the medicament according to the invention may be tablets, hard capsules, soft capsules, enteric capsules, microcapsules, granules, syrups, injections, granules, emulsions, suspensions, solutions and for oral or parenteral administration In the form of a slow-release preparation.
  • the pharmaceutically acceptable carrier in the present invention refers to a pharmaceutically acceptable carrier well known to those skilled in the art.
  • the pharmaceutically acceptable carrier in the present invention includes, but is not limited to, fillers, wetting agents, adhesives, and disintegrating agents. , Lubricants, adhesives, glidants, taste-masking agents, surfactants, preservatives, etc.
  • Fillers include, but are not limited to, lactose, microcrystalline cellulose, starch, powdered sugar, dextrin, mannitol, calcium sulfate, and the like.
  • Wetting agents and binders include, but are not limited to, sodium carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, gelatin, sucrose, polyvinylpyrrolidone, and the like.
  • Disintegrating agents include, but are not limited to, sodium carboxymethyl starch, cross-linked polyvinyl pyrrolidone, croscarmellose sodium, low-substituted hydroxypropyl cellulose, and the like.
  • Lubricants include, but are not limited to, magnesium stearate, micronized silica gel, talc, hydrogenated vegetable oil, polyethylene glycol, magnesium lauryl sulfate, and the like.
  • Binders include, but are not limited to, gum arabic, alginic acid, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, glucose binding agents, dextrin, dextrose, ethyl cellulose, gelatin, liquid glucose, guar Gum, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, magnesium aluminum silicate, maltodextrin, methyl cellulose, polymethacrylate, polyvinylpyrrolidone, pregelatinized starch , Sodium alginate, sorbitol, starch, syrup and tragacanth.
  • Glidants include, but are not limited to, colloidal silica, powdered cellulose, magnesium trisilicate, silica, and talc.
  • Taste-masking agents include, but are not limited to, aspartame, stevioside, fructose, glucose, syrup, honey, xylitol, mannitol, lactose, sorbitol, maltitol, glycyrrhizin.
  • Surfactants include, but are not limited to, Tween-80, Poloxamer.
  • Preservatives include, but are not limited to, paraben, sodium benzoate, potassium sorbate, and the like.
  • treatment generally refers to obtaining the desired pharmacological and / or physiological effect.
  • the effect may be preventive based on the complete or partial prevention of the disease or its symptoms; and / or based on the partial or complete stabilization or cure of the disease and / or side effects due to the disease, which may be therapeutic.
  • Treatment encompasses any treatment of a patient's disease, including: (a) preventing a disease or symptom that occurs in a patient who is susceptible to a disease or condition that has not yet been diagnosed; (b) suppressing the symptoms of the disease, That is, preventing its development; or (c) alleviating the symptoms of the disease, that is, causing the disease or the symptoms to deteriorate.
  • the mannuronic acid oligosaccharide composition for treating vascular dementia comprises a mannuronic acid having the formula (III) or a pharmaceutically acceptable salt thereof:
  • n is an integer selected from 1-9
  • m is selected from 0, 1 or 2
  • m ' is selected from 0 or 1
  • the M-stage intermediate of the raw materials used in the present invention can be prepared by methods known in the art. For example, the methods disclosed in Chinese Patent Application No.98806637.8 and CN02823707.2.
  • the general method can be simply described as: after the initial degradation of alginic acid, a mixed polysaccharide of polymannuronic acid and polyguluronic acid can be obtained, and after the mixed polysaccharide is precipitated by the acid method, the polyguluraldehyde can be removed Acid, further purification can obtain a homopolymannuronic acid with a purity of more than 90%, that is, an M-stage intermediate.
  • the M-stage intermediate is dissolved in an appropriate amount of water at room temperature or under heating conditions, stirred, and ozone is continuously introduced, and the reaction starts.
  • the reaction pH can be adjusted to between 3-13, preferably 4-10, more preferably 6-8, by adding dilute hydrochloric acid or dilute NaOH solution.
  • the temperature is preferably 0-70 ° C, and more preferably 10-45 ° C.
  • the oligosaccharide mixture obtained in step (1) is dissolved, formulated to a concentration of about 10%, separated by a P6 gel chromatography column, and detected by UV, and each effluent component is collected, and components with the same degree of polymerization are combined.
  • Nine components of 2-10 sugars were collected, desalted by G10 gel column chromatography, concentrated on a rotary evaporator, and dried under vacuum.
  • a specific purification preparation process is shown in Example 4. These column chromatography, desalting and drying operations are known to those skilled in the art.
  • the oligosaccharides with a single degree of polymerization were used to evaluate the pharmacological activity of anti-vascular dementia animal models, and the activity of hexasaccharide was found to be the best.
  • the results show that the oligosaccharide composition of the present invention and the comparative test sample are significantly better than the most active hexasaccharide in a single degree of polymerization oligosaccharide.
  • the composition containing disaccharides and trisaccharides is slightly less active than hexasaccharides.
  • oligosaccharides can play a synergistic effect after compounding, when the proportion of di-hexasaccharides in the composition is higher than 60%, and the proportion of di- and trisaccharides is not higher than 60% , The activity of the composition is the highest; but when the proportion of di- and trisaccharides exceeds 60%, the activity of the composition will also decrease.
  • mice Male C57BL / 6 mice, weighing 22 ⁇ 2g, were randomly divided into: sham operation group, 30 minutes bilateral common carotid artery occlusion (BCCAo) model group (referred to as 30min BCCAo group), administration group, There are 10 animals in each group. After the animals were divided into groups, mice in the sham operation group and the 30-minute BCCAo group were perfused with distilled water once a day. After 5 consecutive days of intragastric administration, BCCAo surgery was performed. The mice in the administration group were given the corresponding drugs by gavage. They were administered by gavage once a day. After 5 days of continuous administration, BCACo surgery was performed.
  • BCCAo bilateral common carotid artery occlusion
  • the dark avoidance test was performed on the 7th day after BCCAo, and the Morris water maze test was started on the 13th day to evaluate the improvement effect of mannuronic acid composition on the learning and memory ability of mice.
  • the mice were sacrificed and the brain tissues were fixed.
  • the staining of the hippocampal nerve cells after BCCAo and the protective effect of the mannuronic acid composition on the damaged neurons were evaluated by HE staining and other methods.
  • the Morris water maze (MWM) experiment is an experiment that forces experimental animals to swim and learn to find hidden platforms in the water. It is mainly used to test the experimental animals' learning and memory of spatial location and orientation (spatial positioning). ability.
  • the mouse Morris water maze is mainly composed of a cylindrical pool with a diameter of 80cm and a height of 70cm and a movable platform with a diameter of 8cm. A digital camera is connected to the computer over the pool. Before the experiment, inject fresh water into the pool, the water depth is 15cm, and the water surface is 0.5cm higher than the platform surface. Add milk to make the pool water opaque, and keep the platform position unchanged during the experiment.
  • Morris water maze behavior includes the following two test indicators.
  • Place navigation experiment which is used to measure the acquisition ability of mice on water maze learning and memory.
  • the experiment started on the 13th day after BCCAo and lasted 4 days. The mice were trained once in the morning and afternoon in total, 8 times in total. During training, the mouse enters the pool at 1/2 radian of the west quadrant, and heads into the pool wall. If the platform is not found within 120 seconds, the experimenter will guide them to the platform and leave it for 30 seconds to guide their learning and memory.
  • the experimental observation and recording of the route map and the time required for the mice to find and climb onto the platform, that is, the escape latency and swimming speed of the Morris water maze experiment were recorded.
  • the Morris water maze experiment avoidance latency refers to the time from when a mouse enters the water to when it finds a platform. The shorter the escape latency of the Morris water maze experiment, the better the animals' memory.
  • the rats in the other groups were anesthetized with intraperitoneal injection of chloral hydrate 350mg / kg, and the left side was fixed on the rat plate, and the outer ear canal and eyes were under the operating microscope Cut the skin at the midpoint of the iliac crest to expose the iliac arch. Use a small retractor to spread the phosphorous bone and the mandible. Open a 2mm ⁇ 2mm bone window at the base of the skull, tear the dura, and expose the brain. In the middle artery, the middle cerebral artery of one side was blocked by electrocoagulation with a high-frequency electrosurgical knife to cause cerebral ischemia. The intraoperative and postoperative room temperature were strictly controlled at 24-25 °C. Each group continued to administer or administer distilled water according to their respective pre-operative dosing schedules. Morris water maze experiments were performed in each group on the 11th day after surgery.
  • Step 1) Preparation of mannuronic acid oligosaccharide mixture
  • the method of preparing the M-stage intermediate as disclosed in the previous patent is briefly described as follows: 5Kg of sodium alginate is prepared into a solution of about 10%, and diluted hydrochloric acid is added to adjust the pH to about 3.0, and the temperature is raised to 80 ° C, stirred, and reacted. 10hr, stop heating, cool to room temperature, add NaOH to adjust pH to 9.0, add dilute hydrochloric acid to adjust pH to 2.85, centrifuge at 5000rpm for 10min, collect supernatant, add HCl to adjust pH to 1.0, centrifuge, collect precipitate, rotate The evaporator was concentrated and dried under vacuum to obtain 1500 g of M-stage intermediate.
  • Step 2) Proportion and structure analysis of oligosaccharides with various polymerization degrees in mannuronic acid product A
  • disaccharides-decasaccharides are represented by dp2-dp10, respectively, dp2 is 19%, dp3 is 25%, dp4 is 22%, dp5 is 13%, dp6 is 9%, dp7 is 6%, and dp8 is 3 %, Dp9 is 2%, and dp10 is 1%.
  • Step 3) LC-MS analysis of the structure of oligosaccharides with various degrees of polymerization in Mannuronic acid product A
  • Mass spectrometry conditions Agilent 6540 QTOF; ion source: ESI collision voltage 120V; negative ion mode.
  • the acquisition signal (m / z) width is 100-1000.
  • Example 1 100 g of the M-stage intermediate in Example 1 was weighed, dissolved in distilled water, and prepared into a volume of 0.8 L. The solution was adjusted to pH 4.0 with NaOH and reacted at room temperature at 25 ° C. The gas flow at the outlet of the oxygen cylinder and the power of the ozone generator were adjusted so that the ozone mass concentration flow reached 1 g / hr and passed into the reaction solution. After 10 hours of reaction, stop introducing ozone, add appropriate amount of water to adjust the solution concentration to about 15%, and filter with an ultrafiltration membrane with a molecular weight cut off of 1000 Da. Collect the impervious liquid, concentrate on a rotary evaporator, and dry in vacuo to obtain 80 g of mannaldehyde Acid Product B.
  • Example 1 100 g of the M-stage intermediate in Example 1 was weighed, dissolved in distilled water, and then a 1.5 L volume solution was prepared. The pH was adjusted to 9.0 with NaOH, and the reaction was performed at 45 ° C in a water bath. The gas flow at the outlet of the oxygen cylinder and the power of the ozone generator were adjusted so that the ozone mass concentration flow reached 3 g / hr and passed into the reaction solution. After reacting for 2 hours, stop introducing ozone, add an appropriate amount of water to adjust the solution concentration to about 5%, and filter through an ultrafiltration membrane with a molecular weight cut-off of 3000 Da. Collect the impervious liquid, concentrate on a rotary evaporator, and dry in vacuo to obtain 60 g of mannaldehyde. Acid Product C.
  • a method for preparing a single degree of mannanuronic acid oligosaccharide is as follows:
  • Sample preparation Take 300g from the mannuronic acid product A prepared in Example 1, dissolve it with water, configure it into a 1000mL concentrated solution, and place it in a 4 ° C refrigerator for later use. After each use, 50 mL was taken out and diluted with water, and then filtered with 0.22um ultrafiltration membrane.
  • Chromatographic separation conditions The chromatograph is AKTA pure 150 (purchased from GE), equipped with UV detector and automatic collector. Separation chromatographic column: 1.2kg BioGel P6 (purchased from Bole Company) mixed with deionized water, vacuum degassed, manually packed into a glass column (10cm inner diameter), washed with pure water 10 times the column volume, the column bed is stable , The height is 1.0m. Then use 0.02M NaCl solution as the mobile phase. After equilibrating 10 times the column volume, start loading.
  • the flow rate of the pump is set to 1 mL / min. After 100 mL of the sample solution is pumped to the top of the column by the pump that comes with the chromatograph, switch to the mobile phase and elute at a flow rate of 5 mL / min. After the volume of the stagnant water flowed out, automatic collection was started, and 50 mL was collected per tube.
  • Composition product D Mannuronic acid oligosaccharide having a single degree of polymerization prepared in Example 4 was accurately weighed according to the degree of polymerization from disaccharide to decasaccharide, and the weight of each sugar was as follows: 3.0g of sugar, 3.0g of trisaccharide, 1.5g of tetrasaccharide, 1.5g of pentasaccharide, 0.4g of hexasaccharide, 0.2g of heptose, 0.2g of octose, 0.1g of nonaperose, 0.1g of decasuose, 10g of composition Product D.
  • a fresh oxidant copper hydroxide was prepared by adding 25 ml of a 5% (weight percent) copper sulfate solution to 50 ml of a 10% (weight percent) sodium hydroxide solution and immediately mixing.
  • the fresh oxidizing agent copper hydroxide was immediately added to 40 ml of the above-mentioned 5% (wt%) algin gum oligosaccharide solution, and simultaneously heated by a boiling water bath until no red brick precipitate was generated.
  • the reaction system was centrifuged to remove a precipitate to obtain a supernatant.
  • the eluent as a mobile phase was 0.2 mol ⁇ L-1NH 4 HCO. 3 .
  • the eluate was collected from the column chromatography using a plurality of 5 ml test tubes in order, and then the sugar content of the eluate in each of the headers was detected by the sulfuric acid-carbazole method. According to the detection results, eluates containing alginate oligosaccharide components with different molecular weights were collected. The eluates containing alginate oligosaccharide components with different molecular weights were respectively concentrated under reduced pressure and freeze-dried, and component 1 was discarded to obtain alginate oligosaccharide components 2-12 having different molecular weights respectively.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PCT/CN2019/093813 2018-06-29 2019-06-28 甘露糖醛二酸的组合物在治疗血管性痴呆症中的应用 Ceased WO2020001643A1 (zh)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020217001545A KR20210040039A (ko) 2018-06-29 2019-06-28 혈관성 치매 치료에서의 만누론 이산 조성물의 용도
US17/256,738 US11406651B2 (en) 2018-06-29 2019-06-28 Use of mannuronic diacid composition in treatment of vascular dementia
JP2020572804A JP2021528458A (ja) 2018-06-29 2019-06-28 血管性認知症の治療におけるマンヌロン二酸組成物の使用
EP19826046.5A EP3815694A4 (en) 2018-06-29 2019-06-28 USE OF A MANNURONIC DIACID COMPOSITION IN THE TREATMENT OF VASCULAR DEMENTIA
AU2019296854A AU2019296854A1 (en) 2018-06-29 2019-06-28 Use of mannuronic diacid composition in treatment of vascular dementia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810711863.8A CN110652523A (zh) 2018-06-29 2018-06-29 甘露糖醛二酸的组合物在治疗血管性痴呆症中的应用
CN201810711863.8 2018-06-29

Publications (1)

Publication Number Publication Date
WO2020001643A1 true WO2020001643A1 (zh) 2020-01-02

Family

ID=68985857

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/093813 Ceased WO2020001643A1 (zh) 2018-06-29 2019-06-28 甘露糖醛二酸的组合物在治疗血管性痴呆症中的应用

Country Status (7)

Country Link
US (1) US11406651B2 (https=)
EP (1) EP3815694A4 (https=)
JP (1) JP2021528458A (https=)
KR (1) KR20210040039A (https=)
CN (1) CN110652523A (https=)
AU (1) AU2019296854A1 (https=)
WO (1) WO2020001643A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835403B2 (en) 2004-03-24 2014-09-16 Meiyu Geng Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same
CN106344593A (zh) 2015-07-17 2017-01-25 上海绿谷制药有限公司 褐藻胶寡糖及其衍生物在治疗血管性痴呆中的应用
CN106344592A (zh) 2015-07-17 2017-01-25 上海绿谷制药有限公司 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6977059B2 (ja) * 2016-12-30 2021-12-08 シャンハイ、グリーン、バレー、ファーマスーティカル、カンパニー、リミテッドShanghai Green Valley Pharmaceutical Co., Ltd. マンヌロン二酸の組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835403B2 (en) 2004-03-24 2014-09-16 Meiyu Geng Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same
CN106344593A (zh) 2015-07-17 2017-01-25 上海绿谷制药有限公司 褐藻胶寡糖及其衍生物在治疗血管性痴呆中的应用
CN106344592A (zh) 2015-07-17 2017-01-25 上海绿谷制药有限公司 还原端1位为羧基的甘露糖醛酸寡糖及其衍生物在治疗帕金森氏症中的应用

Also Published As

Publication number Publication date
EP3815694A4 (en) 2022-03-02
US11406651B2 (en) 2022-08-09
KR20210040039A (ko) 2021-04-12
US20210268006A1 (en) 2021-09-02
EP3815694A1 (en) 2021-05-05
CN110652523A (zh) 2020-01-07
JP2021528458A (ja) 2021-10-21
AU2019296854A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
JP6977059B2 (ja) マンヌロン二酸の組成物
JP7672226B2 (ja) アルギン酸オリゴサッカリン二酸の組成物
CN106344593B (zh) 褐藻胶寡糖及其衍生物在制备治疗血管性痴呆药物中的应用
US11406659B2 (en) Use of mannuronic diacid composition in treatment of inflammation
US11406651B2 (en) Use of mannuronic diacid composition in treatment of vascular dementia
WO2020001640A1 (zh) 甘露糖醛二酸的组合物在治疗帕金森氏症中的应用
WO2020001644A1 (zh) 甘露糖醛二酸的组合物在治疗糖尿病中的应用
HK40014916A (en) Use of a composition of oligomeric mannuronic diacid for treating vascular dementia
WO2020001639A1 (zh) 甘露糖醛二酸的组合物在治疗疼痛中的应用
HK40014917A (en) Use of a composition of oligomeric mannuronic diacid for treating parkinson's disease
HK40016251A (en) Use of a composition of mannuronic diacids in the treatment of pain
HK40014915A (en) Use of a composition of oligomeric mannuronic diacid for treating inflammation
HK40016250A (en) Use of a composition of mannuronic diacids in the treatment of diabetes
EA041420B1 (ru) Композиции маннуроновой дикислоты, способы ее получения и использования

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19826046

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020572804

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019296854

Country of ref document: AU

Date of ref document: 20190628

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2019826046

Country of ref document: EP